News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
News UK biotech Astex celebrates as Novartis breast cancer drug a... Cambridge firm played key role in discovery of potential blockbuster Kisqali.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News US drug revenues far exceed R&D spend - report Analysis questions industry's rationale for high US prices.
Views & Analysis The first decade of biosimilars – and beyond Sandoz’s CEO Richard Francis on the latest developments in biosimilars.
News Kite and Fosun appoint leader for CAR-T debut in China But rival Juno finally gives up on lead therapy.
News Sanofi abandons phase 3 trial of neurology drug riliprubart Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
